1. Management of Glioblastoma

4. Standard of Care for Newly Diagnosed GBM

5. Standard of Care for Newly Diagnosed GBM (cont.)

6. Bevacizumab Not Supported for Newly-Diagnosed GBM

7. Bevacizumab + Lomustine

8. Second-Line Therapy for GBM

9. Newly-Diagnosed GBM

10. Addition of Bevacizumab to First-Line Radiotherapy + Temozolomide Retrospective Analysis of the AVAglio Trial

11. Tumor Treating Fields

12. ABT-414 Phase 1 Trial of EGFR-Targeted Monoclonal Antibody Drug Conjugate

13. ABT-414 Adverse Events

14. Nivolumab: PD-1 Antibody Mechanism of Action

15. Nivolumab Checkmate-143: Phase 1 Trial

16. Pembrolizumab: PD-1 Antibody KEYNOTE-28 (Phase 2 Trial)

17. PD-L1 Antibody Ongoing Phase 2 Study of Durvalumab

18. Case Reports and PD-L1 as a Biomarker

19. Rindopepimut: EGFRvIII-Targeted Vaccine

20. TAVAREC: Temozolomide ± Bevacizumab in Grade 2/3 Glioma

21. CATNON Phase 3 Trial: Concurrent and Adjuvant Temozolomide in Anaplastic Grade 3 Glioma

22. IDH Mutations: Key Therapeutic Targets

23. Concluding Remarks

24. Abbreviations

25. Abbreviations (cont)